<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548842" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548842/" /><meta name="ncbi_pagename" content="Olanzapine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Olanzapine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Olanzapine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/07/01" /><meta name="citation_pmid" content="31644149" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548842/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Olanzapine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/07/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548842/" /><meta name="description" content="Olanzapine is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness. Olanzapine is not infrequently associated with serum aminotransferase elevations during therapy and there have been rare instances of clinically apparent acute liver injury linked to its use." /><meta name="og:title" content="Olanzapine" /><meta name="og:type" content="book" /><meta name="og:description" content="Olanzapine is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness. Olanzapine is not infrequently associated with serum aminotransferase elevations during therapy and there have been rare instances of clinically apparent acute liver injury linked to its use." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548842/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Olanzapine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548842/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C884204689E110000000000A80039.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548842_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548842_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Ofloxacin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Olaparib/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548842_"><span class="title" itemprop="name">Olanzapine</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 1, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Olanzapine.OVERVIEW"><h2 id="_Olanzapine_OVERVIEW_">OVERVIEW</h2><div id="Olanzapine.Introduction"><h3>Introduction</h3><p>Olanzapine is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness. Olanzapine is not infrequently associated with serum aminotransferase elevations during therapy and there have been rare instances of clinically apparent acute liver injury linked to its use.</p></div><div id="Olanzapine.Background"><h3>Background</h3><p>Olanzapine (oh lan' za peen) is a thienobenzodiazepine derivative which appears to act as a dopamine (D1-4) and serotonic (5-HT2A/2C and 5-HT6) receptor antagonist. Olanzapine was approved for use in schizophrenia in the United States in 1996 and continues to be used for this indication. Olanzapine is also used in mood disturbances of bipolar I disorder and in combination with other agents for treatment of resistant depression in adults. Olanzapine is available as tablets of 2.5, 5, 7.5, 10, 15 and 20 mg generically and under the brand name Zyprexa; formulations for parenteral use and orally disintegrating tablets are also available, as are fixed combinations with antidepressants such as fluoxetine (Symbyax and generics). A typical dose regimen is 5 to 20 mg daily, starting with a low dose and increasing cautiously. Common side effects include sedation, increased appetite, weight gain, constipation, orthostatic hypotension, dizziness, dry mouth, weakness and akathisia (restlessness). Uncommon but potentially severe adverse reactions include excess mortality in the elderly with dementia, suicidal ideation and behaviors, neuroleptic malignant syndrome, hypersensitivity reactions including drug-rash, eosinophilia and systemic symptoms (DRESS) syndrome, metabolic abnormalities including hyperglycemia and dyslipidemia, seizures, leukopenia and neutropenia, and hyperprolactinemia.</p></div><div id="Olanzapine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p><a class="def" href="/books/n/livertox/glossary/def-item/glossary.liver-test-abnormalities/">Liver test abnormalities</a> have been reported to occur in 10% to 50% of patients on long term therapy with olanzapine. These abnormalities are usually mild, asymptomatic and transient, and can reverse even with continuation of medication. In addition, instances of more marked elevations in serum aminotransferase levels and clinically apparent hepatitis with jaundice have been reported in patients taking olanzapine. The pattern of serum enzyme elevations has ranged from hepatocellular to mixed and even cholestatic. Allergic manifestations (rash, fever, eosinophilia) and autoimmune markers are uncommon. The time to onset of liver injury with olanzapine therapy has varied widely, from a few weeks to a year after starting. In all cases, the injury has resolved rapidly with drug discontinuation. Cases with a long latency and accompanied by significant weight gain may represent nonalcoholic fatty liver disease, rather than olanzapine hepatotoxicity.</p></div><div id="Olanzapine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which olanzapine causes serum aminotransferase elevations is not known. Some instances of <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations occurring on olanzapine therapy may be due to nonalcoholic fatty liver disease caused by weight gain that occurs in at least one-quarter of treated patients generally during the first 1 to 2 years of therapy. Weight gain averages 1 kg/month and can be extreme (20 to 30 kg). Olanzapine has extensive hepatic metabolism, partially via the cytochrome P450 system, and some cases of clinically apparent hepatotoxicity may be due to production of a toxic intermediate of metabolism.</p></div><div id="Olanzapine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur on olanzapine therapy are usually self-limited and rarely require dose modification or discontinuation of therapy. No instances of acute liver failure, chronic liver disease or vanishing bile duct syndrome have been attributed to olanzapine. Switching to other atypical antipsychotics is occasionally, but not always associated with recurrence of hepatic injury.</p><p>Drug Class: <a href="/books/n/livertox/AntipsychoticAgents/">Antipsychotic Agents</a>, Atypicals</p></div></div><div id="Olanzapine.CASE_REPORT"><h2 id="_Olanzapine_CASE_REPORT_">CASE REPORT</h2><div id="Olanzapine.Case_1_Acute_liver_injury_due"><h3>Case 1. Acute liver injury due to olanzapine.(<a class="bk_pop" href="#Olanzapine.REF.1">1</a>)</h3><p>A 47 year old patient with a history of paranoid schizophrenia developed jaundice 11 months after starting olanzapine (10 mg daily). She had a vague history of alcoholic liver disease. Laboratory test results showed a total bilirubin of 7.5 mg/dL, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 173 U/L and alkaline phosphatase of 178 U/L (Table). Olanzapine was stopped and haloperidol started in its place. Tests for viral hepatitis and autoantibodies were negative. Within 2 weeks, serum bilirubin levels had fallen and all test results returned to normal when she was seen 3 months later.</p><div id="Olanzapine.Key_Points"><h4>Key Points</h4><div id="Olanzapine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548842/table/Olanzapine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Olanzapine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Olanzapine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Olanzapine.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olanzapine</td></tr><tr><th id="hd_b_Olanzapine.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Olanzapine.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mixed (R=3.0)</td></tr><tr><th id="hd_b_Olanzapine.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Olanzapine.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (jaundice and hospitalization)</td></tr><tr><th id="hd_b_Olanzapine.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Olanzapine.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 months</td></tr><tr><th id="hd_b_Olanzapine.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Olanzapine.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Olanzapine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Olanzapine.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548842/table/Olanzapine.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Olanzapine.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Olanzapine.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Olanzapine.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Olanzapine.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Olanzapine.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a><br />(U/L)</th><th id="hd_h_Olanzapine.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Olanzapine.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Olanzapine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 months</td><td headers="hd_h_Olanzapine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Olanzapine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">173</td><td headers="hd_h_Olanzapine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">178</td><td headers="hd_h_Olanzapine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.5</td><td headers="hd_h_Olanzapine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Olanzapine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Olanzapine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td><td headers="hd_h_Olanzapine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">775</td><td headers="hd_h_Olanzapine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">181</td><td headers="hd_h_Olanzapine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.7</td><td headers="hd_h_Olanzapine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Olanzapine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 months</td><td headers="hd_h_Olanzapine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Olanzapine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">79</td><td headers="hd_h_Olanzapine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">161</td><td headers="hd_h_Olanzapine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Olanzapine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haloperidol</td></tr><tr><td headers="hd_h_Olanzapine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 months</td><td headers="hd_h_Olanzapine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 weeks</td><td headers="hd_h_Olanzapine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_Olanzapine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Olanzapine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4</td><td headers="hd_h_Olanzapine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Olanzapine.Td_1_1_1_1 hd_h_Olanzapine.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Olanzapine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;42</b></td><td headers="hd_h_Olanzapine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;130</b></td><td headers="hd_h_Olanzapine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Olanzapine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Olanzapine.Comment"><h4>Comment</h4><p>A brief case report with missing information but somewhat typical presentation of drug induced liver injury with a mixed hepatocellular-cholestatic pattern. Olanzapine is a common cause of transient serum aminotransferase elevations, but has rarely been implicated in cases of clinically apparent liver injury with jaundice.</p></div></div></div><div id="Olanzapine.PRODUCT_INFORMATION"><h2 id="_Olanzapine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Olanzapine &#x02013; Generic, Zyprexa&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antipsychotic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Olanzapine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Olanzapine.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Olanzapine_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Olanzapine.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548842/table/Olanzapine.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Olanzapine.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Olanzapine.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Olanzapine.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Olanzapine.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Olanzapine.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Olanzapine.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olanzapine</td><td headers="hd_h_Olanzapine.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135017274" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">132539-06-1</a></td><td headers="hd_h_Olanzapine.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C17-H20-N4-S</td><td headers="hd_h_Olanzapine.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135017274" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135017274" alt="image 135017274 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Olanzapine.CITED_REFERENCE"><h2 id="_Olanzapine_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Olanzapine.REF.1">Dom&#x000ed;nguez-Jim&#x000e9;nez JL, Puente-Guti&#x000e9;rrez JJ, Pelado-Garc&#x000ed;a EM, Cuesta-Cubillas D, Garc&#x000ed;a-Moreno AM. Liver toxicity due to olanzapine. <span><span class="ref-journal">Rev Esp Enferm Dig. </span>2012;<span class="ref-vol">104</span>:617–8.</span> [<a href="/pubmed/23368661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23368661</span></a>]</div></dd></dl></div><div id="Olanzapine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Olanzapine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 01 July 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Olanzapine.REF.meyer.2018">Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 279-302.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.larry.2013">Larry D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 443-62.<div><i>(Review of hepatotoxicity of psychiatric agents mentions that olanzapine has rarely been implicated in causing clinically apparent hepatic toxicity).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.beasley.1997.13">Beasley CM, Tollefoson GD, Tran PV. Safety of olanzapine. <span><span class="ref-journal">J Clin Psychiatry. </span>1997;<span class="ref-vol">58</span> Suppl 10:13–7.</span> [<a href="/pubmed/9265911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9265911</span></a>]<div><i>(Retrospective analysis of registration trials of olanzapine as therapy of schizophrenia; weight gain of at least 7% in 40.5% of patients treated with olanzapine, 12.4% with haloperidol and 3.1% with placebo; ALT elevations occurred in 9.4% of olanzapine treated patients, usually within 1-2 weeks of starting and rising above 200 U/L in 2.1%; no cases of clinically apparent hepatitis).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.mcelroy.1998.119">McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, Suppes T, et al.  Olanzapine in treatment-resistant bipolar disorder. <span><span class="ref-journal">J Affect Disord. </span>1998;<span class="ref-vol">49</span>:119–22.</span> [<a href="/pubmed/9609675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9609675</span></a>]<div><i>(Open label study of olanzapine in 14 patients, no information on liver test abnormalities).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.allison.1999.1686">Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. <span><span class="ref-journal">Am J Psychiatry. </span>1999;<span class="ref-vol">156</span>:1686–96.</span> [<a href="/pubmed/10553730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10553730</span></a>]<div><i>(Systematic review of 81 articles on weight change with antipsychotics, using change after 10 weeks to compare agents: clozapine +5.7, olanzapine +4.2, chlorpromazine +4.2, quetiapine +2.5, risperidone +1.7, loxapine +0.6, haloperidol +0.5, ziprasidone +0.3, molindone -0.1, and pimozide -2.7 kg).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.marcus.1999.697">Marcus EL, Vass A, Zislin J. Marked elevation of serum creatinine kinase associated with olanzapine therapy. <span><span class="ref-journal">Ann Pharmacother. </span>1999;<span class="ref-vol">33</span>:697–700.</span> [<a href="/pubmed/10410183" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10410183</span></a>]<div><i>(39 year old man was found to have CPK 2252 U/L without symptoms 3 days after starting olanzapine [bilirubin not reported, AST 65 U/L], resolving within a week of stopping).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.conley.2000.26">Conley RR, Meltzer HY. Adverse events related to olanzapine. <span><span class="ref-journal">J Clin Psychiatry. </span>2000;<span class="ref-vol">61</span> Suppl 8:26–9.</span> [<a href="/pubmed/10811240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10811240</span></a>]<div><i>(Review of side effects of olanzapine from large registration trials; weight gain averaged 2-3 kg, but was dose dependent and averaged 12 kg with high dose at one year; &#x0201c;Transient, non-dose-dependent, asymptomatic elevations in liver enzymes have also been noted in olanzapine-treated patients&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.balestrieri.2000.499">Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. <span><span class="ref-journal">Hum Psychopharmacol. </span>2000;<span class="ref-vol">15</span>:499–512.</span> [<a href="/pubmed/12404619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12404619</span></a>]<div><i>(Review on efficacy and safety of antipsychotic agents; transient elevations in ALT in 9.4% of olanzapine treated patients, but no clinical symptoms or jaundice reported).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.gerber.2000.249">Gerber JE, Cawthon B. Overdose and death with olanzapine: two case reports. <span><span class="ref-journal">Am J Forensic Med Pathol. </span>2000;<span class="ref-vol">21</span>:249–51.</span> [<a href="/pubmed/10990286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10990286</span></a>]<div><i>(Two patients found dead after olanzapine overdose with high serum levels; no evidence of hepatic toxicity mentioned).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.cadario.2000.85">Cadario B. Olanzapine (Zyprexa): suspected serious reactions. <span><span class="ref-journal">CMAJ. </span>2000;<span class="ref-vol">163</span>:85–6, 89-90.</span> [<a href="/pubmed/10920744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10920744</span></a>]<div><i>(Among 153 adverse event reports due to olanzapine, there were 22 deaths but none attributed to liver injury; 9 cases of ALT elevation, only 2 above twice normal and one with jaundice [bilirubin not given, ALT 527 U/L, alkaline phosphatase 211 U/L] after 5 months of treatment, without further details or follow up information).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.raz.2001.156">Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. <span><span class="ref-journal">Am J Med Sci. </span>2001;<span class="ref-vol">321</span>:156–8.</span> [<a href="/pubmed/11217818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11217818</span></a>]<div><i>(34 year old man developed rash, fever, and eosinophilia 2 months after starting olanzapine [bilirubin 1.1 mg/dL, ALT 518 U/L, Alk P 68 U/L], resolving upon stopping olanzapine, but with confounding history of amoxicillin exposure; tolerated risperidone in follow up).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.dumortier.2002.542">Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, et al.  <span><span class="ref-journal">Encephale. </span>2002;<span class="ref-vol">28</span>:542–51.</span> [Hepatic tolerance of atypical antipsychotic drugs] [<a href="/pubmed/12506267" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12506267</span></a>]<div><i>(Review of reports of liver injury due to atypical antipsychotics).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.mouradianstamatiadis.2002.1409">Mouradian-Stamatiadis L, Dumortier G, Januel D, Delmas BA, Cabaret W. Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. <span><span class="ref-journal">Prog Neuropsychopharmacol Biol Psychiatry. </span>2002;<span class="ref-vol">26</span>:1409–11.</span> [<a href="/pubmed/12502031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12502031</span></a>]<div><i>(23 hospitalized patients on atypical antipsychotics, 6 had ALT or AST elevations by day 14, ALT 48-158 U/L, 2 on risperidone, 2 olanzapine and one amisulpride; 1 on risperidone required discontinuation).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.kelly.2003.181">Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. <span><span class="ref-journal">Ann Clin Psychiatry. </span>2003;<span class="ref-vol">15</span>:181–6.</span> [<a href="/pubmed/14971863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14971863</span></a>]<div><i>(Crossover study of 8 weeks of olanzapine vs clozapine in 13 patients; ALT elevations occurred in 66% of clozapine, but no olanzapine treated patient; weight gain was greater with olanzapine [~3.4 kg] than clozapine [~1.4 kg]).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF16">Choice of an antipsychotic. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2003;<span class="ref-vol">45</span>:102–4.</span> [<a href="/pubmed/14679353" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14679353</span></a>]<div><i>(Despite a similar chemical structure to clozapine, olanzapine does not appear to cause agranulocytosis; weight gain is common and can be marked; &#x0201c;Increases in hepatic transaminase activity have been reported&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.gonzalezheydrich.2003.1227">Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. <span><span class="ref-journal">J Am Acad Child Adolesc Psychiatry. </span>2003;<span class="ref-vol">42</span>:1227–33.</span> [<a href="/pubmed/14560173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14560173</span></a>]<div><i>(52 children receiving olanzapine and/or valproate; ALT elevations occurred in all 12 on combination, 59% on olanzapine alone and 26% on valproate alone; only 2 had ALT &#x0003e;3 times ULN, one with pancreatitis and one with steatohepatitis, resolving with stopping olanzapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.haberfellner.2003.851">Haberfellner EM, Honsig T. Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics. <span><span class="ref-journal">J Clin Psychiatry. </span>2003;<span class="ref-vol">64</span>:851.</span> [<a href="/pubmed/12934993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12934993</span></a>]<div><i>(Three men, ages 24 to 31 years with weight gain [24-26 kg] on olanzapine or risperidone for ~4 years had ALT elevations [47-91 U/L]; ultrasound showed evidence of fatty liver).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.kolpe.2003.210">Kolpe M, Ravasia S. Effect of olanzapine on the liver transaminases. <span><span class="ref-journal">Can J Psychiatry. </span>2003;<span class="ref-vol">48</span>:210.</span> [<a href="/pubmed/12728748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12728748</span></a>]<div><i>(Two women, ages 37 and 62 years, developed ALT elevations [237 and 179 U/L] after ~1 month of olanzapine therapy, resolving rapidly with discontinuation; no symptoms and bilirubin normal).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.prior.2003.99">Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. <span><span class="ref-journal">J Psychiatry Neurosci. </span>2003;<span class="ref-vol">28</span>:99–112.</span> [<a href="/pmc/articles/PMC161731/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC161731</span></a>] [<a href="/pubmed/12670127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12670127</span></a>]<div><i>(Review of the interactions of the atypical antipsychotics with the P450 system; clozapine metabolized by CYP1A2 and 3A4 and possibly 2C9 and 2D6; risperidone by CYP2D6 and possibly 3A4; olanzapine by CYP1A2 and possibly 2D6; quetiapine and ziprasidone by CYP3A4).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.jadallah.2003.357">Jadallah KA, Limauro DL, Colatrella AM. Acute hepatocellular-cholestatic liver injury after olanzapine therapy. <span><span class="ref-journal">Ann Intern Med. </span>2003;<span class="ref-vol">138</span>:357–8.</span> [<a href="/pubmed/12585842" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12585842</span></a>]<div><i>(78 year old woman developed fever, nausea and abdominal pain 13 days after starting olanzapine [bilirubin 1.3 rising to 9.1 mg/dL, ALT 204 to 965 U/L, Alk P 189 to 488 U/L], resolving within 4 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.tchernichovsky.2004.173">Tchernichovsky E, Sirota P. Hepatotoxicity, leucopenia and neutropenia associated with olanzapine therapy. <span><span class="ref-journal">Int J Psychiatry Clin Pract. </span>2004;<span class="ref-vol">8</span>:173–7.</span> [<a href="/pubmed/24941207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24941207</span></a>]<div><i>(37 year old woman with severe schizophrenia developed abnormal liver tests [bilirubin 1.5 mg/dL, ALT 102 U/L, Alk P 461 U/L] 19 days after starting olanzapine, which was not stopped until 11 weeks later when she had pancytopenia; recurrence on restarting olanzapine one year later [bilirubin 1.6 mg/dL, AST 110, Alk P 270 U/L, neutropenia and fever], resolving in several weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.bender.2004.s46">Bender S, Grohmann R, Engel RR, Degner D, Dittmann-Balcar A, Ruther E. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. <span><span class="ref-journal">Pharmacopsychiatry. </span>2004;<span class="ref-vol">37</span> Suppl 1:S46–53.</span> [<a href="/pubmed/15052514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15052514</span></a>]<div><i>(Review of severe adverse drug reactions among 35,293 inpatients reported to AMSP; side effects were more common with atypicals [0.5-0.9%] than typical antipsychotics [0.02-0.2%]; increased liver enzymes was the most common adverse reaction to olanzapine, 4th in frequency to clozapine, 6th to haloperidol, 7th to risperidone; no mention of hepatitis or acute liver failure).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.pae.2005.173">Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, Lee C, et al.  Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. <span><span class="ref-journal">Int Clin Psychopharmacol. </span>2005;<span class="ref-vol">20</span>:173–6.</span> [<a href="/pubmed/15812269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15812269</span></a>]<div><i>(Retrospective analysis found ALT elevations more common among 145 patients on olanzapine [25%] than 298 on risperidone [13%] and particularly &#x0003e;3 times ULN [7.6% vs 2.8%]; no instances of jaundice or hepatitis).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.perlis.2006.1747">Perlis RH, Baker RW, Zarate CA Jr, Brown EB, Schuh LM, Jamal HH, Tohen M. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. <span><span class="ref-journal">J Clin Psychiatry. </span>2006;<span class="ref-vol">67</span>:1747–53.</span> [<a href="/pubmed/17196055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17196055</span></a>]<div><i>(3 week trial of olanzapine [n=165] vs risperidone [n=164] for bipolar illness; greater weight gain [16% vs 4%] and ALT elevations [by mean of 15.7 U/L vs 1 U/L] with olanzapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.green.2006.234">Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, et al. HGDH Study Group.  Olanzapine and haloperidol in first episode psychosis: two-year data. <span><span class="ref-journal">Schizophr Res. </span>2006;<span class="ref-vol">86</span>:234–43.</span> [<a href="/pubmed/16887334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16887334</span></a>]<div><i>(Trial of olanzapine vs haloperidol for 2 years in 263 patients with psychosis; olanzapine more often led to weight gain [15.4 vs 7.5 kg] and ALT elevations [63% vs 29%], but no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.rettenbacher.2006.500">Rettenbacher MA, Baumgartner S, Eder-Ischia U, Edlinger M, Graziadei I, Hofer A, Huber R, et al.  Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. <span><span class="ref-journal">J Clin Psychopharmacol. </span>2006;<span class="ref-vol">26</span>:500–3.</span> [<a href="/pubmed/16974192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16974192</span></a>]<div><i>(Prospective study of 67 patients [21 on olanzapine] started on atypical antipsychotics; ALT elevations were more frequent [and higher] in 14 patients who gained &#x0003e;7% of body weight than in 53 who did not [50% vs 19%]; all elevations were transient, asymptomatic and not associated with bilirubin elevations).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.ozcanli.2006.1163">Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. <span><span class="ref-journal">Prog Neuropsychopharmacol Biol Psychiatry. </span>2006;<span class="ref-vol">30</span>:1163–6.</span> [<a href="/pubmed/16632162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16632162</span></a>]<div><i>(44 year old woman with bipolar illness treated with olanzapine for 3 years developed anorexia and abdominal pain [normal bilirubin, ALT 710 U/L, GGT 56 U/L], resolving 3 weeks after stopping; ALT had been normal previously).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.wright.2007.1518">Wright TM, Vandenberg AM. Risperidone- and quetiapine-induced cholestasis. <span><span class="ref-journal">Ann Pharmacother. </span>2007;<span class="ref-vol">41</span>:1518–23.</span> [<a href="/pubmed/17666578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17666578</span></a>]<div><i>(30 year old man developed jaundice after taking risperidone and lithium for 8 years [bilirubin 4.7 mg/dL, ALT 99 U/L, Alk P 267 U/L], resolving upon switching to ziprasidone, but recurrent jaundice 1 year later 3 weeks after starting quetiapine, having tolerated olanzapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.atasoy.2007.1255">Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. <span><span class="ref-journal">Prog Neuropsychopharmacol Biol Psychiatry. </span>2007;<span class="ref-vol">31</span>:1255–60.</span> [<a href="/pubmed/17600607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17600607</span></a>]<div><i>(Retrospective analysis of 194 patients receiving atypical antipsychotic agents; ALT &#x0003e;3 times normal occurred in 27% often in 1st month; among 33 receiving olanzapine, 30% had ALT elevation, 18% at 6 months, and 2 stopped drug for ALT elevations of 3 times &#x0201c;basal level&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.johnsen.2008.31">Johnsen E, J&#x000f8;rgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. <span><span class="ref-journal">BMC Psychiatry. </span>2008;<span class="ref-vol">8</span>:31.</span> [<a href="/pmc/articles/PMC2386457/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2386457</span></a>] [<a href="/pubmed/18439263" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18439263</span></a>]<div><i>(Systematic review of 16 reports of 10 randomized trials of antipsychotic agents; more weight gain with olanzapine, no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.torrent.2008.4">Torrent C, Amann B, Sanchez-Moreno J, Colom F, Feinares M, Comes M, Rosa AR, et al.  Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. <span><span class="ref-journal">Acta Psychiatr Scand. </span>2008;<span class="ref-vol">118</span>:4–18.</span> [<a href="/pubmed/18498432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18498432</span></a>]<div><i>(Review of frequency of weight gain in patients treated for bipolar disorders, most weight gain occurred with clozapine and olanzapine, but some weight gain also with quetiapine, risperidone, lithium, valproate and gabapentin; not with aripiprazole, ziprasidone, carbamazepine or lamotrigine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.sikich.2008.1420">Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, et al.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. <span><span class="ref-journal">Am J Psychiatry. </span>2008;<span class="ref-vol">165</span>:1420–31.</span> [<a href="/pubmed/18794207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18794207</span></a>]<div><i>(Prospective trial of molindone [1st generation] vs olanzapine or risperidone [2nd generation antipsychotic agents] for schizophrenia in 199 youths found similar rates of efficacy [34-50%], but more weight gain [mean 6.1 kg] and ALT elevations with olanzapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008; severe antidepressants [duloxetine, sertraline, fluoxetine, amitriptyline], but none of the atypical antipsychotic agents, were implicated).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.kantrowitz.2008.761">Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2008;<span class="ref-vol">7</span>:761–9.</span> [<a href="/pubmed/18983222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18983222</span></a>]<div><i>(Review of side effects of olanzapine mentions that weight gain averages 1 kg/month at least for the first year and that ALT elevations occur in 2%).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.kane.2009.572">Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. <span><span class="ref-journal">J Clin Psychiatry. </span>2009;<span class="ref-vol">70</span>:572–81.</span> [<a href="/pubmed/19323965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19323965</span></a>]<div><i>(Controlled trial of olanzapine [n=281] vs aripiprazole [n=285] for 28 weeks at 60 centers; no mention of ALT values).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.parsons.2009.103">Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C. Weight effects associated with antipsychotics: A comprehensive database analysis. <span><span class="ref-journal">Schizophr Res. </span>2009;<span class="ref-vol">110</span>:103–10.</span> [<a href="/pubmed/19321312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19321312</span></a>]<div><i>(Analysis of weight gain in 21 placebo controlled trials [~3300 patients]; average monthly weight gain in pounds was +0.1 with placebo, +0.8 olanzapine, +0.6 risperidone, -0.3 ziprasidone. A 5% increase in weight occurred after one year in 13% of placebo, 39% haloperidol, 20% ziprasidone, 45% risperidone and 60% olanzapine treated subjects).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.flanagan.2008.43">Flanagan RJ. Fatal toxicity of drugs used in psychiatry. <span><span class="ref-journal">Hum Psychopharmacol. </span>2008;<span class="ref-vol">23</span> Suppl 1:43–51.</span> [<a href="/pubmed/18098225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18098225</span></a>]<div><i>(Deaths from fatal poisonings decreased in England and Wales between 1993-2004, antipsychotic overdose fatalities higher for phenothiazines than atypicals; deaths/million prescriptions being 29 for chlorpromazine, 15.5 thioridazine, 3.9 trifluoperazine, 13.3 olanzapine, 21 clozapine and 31.3 quetiapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.lui.2009.394">Lui SY, Tso S, Lam M, Cheung EF. Possible olanzapine-induced hepatotoxicity in a young Chinese patient. <span><span class="ref-journal">Hong Kong Med J. </span>2009;<span class="ref-vol">15</span>:394–6.</span> [<a href="/pubmed/19801701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19801701</span></a>]<div><i>(17 year old man developed jaundice 8 days after starting olanzapine for schizophrenia [bilirubin 7.2 mg/dL, ALT 120 U/L, Alk P 250 rising to 440 U/L], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.g_mez_esp_n.2010.150">G&#x000f3;mez Esp&#x000ed;n R, S&#x000e1;nchez Quiles I, Hallal H, Plaza J. <span><span class="ref-journal">Gastroenterol Hepatol. </span>2010;<span class="ref-vol">33</span>:150–2.</span> [Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection] Spanish. [<a href="/pubmed/19914745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19914745</span></a>]<div><i>(35 year old man with chronic hepatitis C developed asymptomatic rise in ALT [188 to 721 U/L] and GGT [134 to 648 U/L] 2 months after starting clozapine, improving on stopping and recurring one month after starting olanzapine [ALT 166 to 714 U/L], resolving upon stopping again).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.devarbhavi.2010.2396">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <span><span class="ref-journal">Am J Gastroenterol. </span>2010;<span class="ref-vol">105</span>:2396–404.</span> [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India; leading causes were antituberculosis agents [58%], anticonvulsants [11%], and NSAIDs [2%]; 17 cases [5%] were due to olanzapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.mccormack.2010.443">McCormack PL. Olanzapine: in adolescents with schizophrenia or bipolar I disorder. <span><span class="ref-journal">CNS Drugs. </span>2010;<span class="ref-vol">24</span>:443–52.</span> [<a href="/pubmed/20369908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20369908</span></a>]<div><i>(Review of indications, clinical efficacy and safety of olanzapine in adolescents; 3-6 weeks of olanzapine therapy was associated with weight gain in 42% of adolescents and ALT elevations in 23%; average ALT increase was 20 U/L vs -3 U/L with placebo).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.ferrajolo.2010.721">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2010;<span class="ref-vol">70</span>:721–8.</span> [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, olanzapine ranked 16th with 62 reports [adjusted reporting odds ratio of 3.1], and clozapine ranked 38th with 36 cases [0.8]).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, none were attributed to olanzapine or other atypical antipsychotic medications).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.manceaux.2011.s15">Manceaux P, Constant E, Zdanowicz N, Jacques D, Reynaert C. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature. <span><span class="ref-journal">Psychiatr Danub. </span>2011;<span class="ref-vol">23</span> Suppl 1:S15–7.</span> [<a href="/pubmed/21894094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21894094</span></a>]<div><i>(45 year old woman with intermittent mild elevations of ALT during therapy with olanzapine and clozapine [ALT 16-92 U/L, AST 16-46 U/L, GGT 26-269 U/L, bilirubin not given]).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.dom_nguezjim_nez.2012.617">Dom&#x000ed;nguez-Jim&#x000e9;nez JL, Puente-Guti&#x000e9;rrez JJ, Pelado-Garc&#x000ed;a EM, Cuesta-Cubillas D, Garc&#x000ed;a-Moreno AM. Liver toxicity due to olanzapine. <span><span class="ref-journal">Rev Esp Enferm Dig. </span>2012;<span class="ref-vol">104</span>:617–8.</span> [<a href="/pubmed/23368661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23368661</span></a>]<div><i>(47 year old developed jaundice 11 months after starting olanzapine [bilirubin 7.5 mg/dL, ALT 173 U/L, Alk P 178 U/L], resolving within 3 months of stopping: Case 1).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.marwick.2012.244">Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. <span><span class="ref-journal">Clin Neuropharmacol. </span>2012;<span class="ref-vol">35</span>:244–53.</span> [<a href="/pubmed/22986798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22986798</span></a>]<div><i>(Systematic review of the literature found rates of any serum enzyme elevation during antipsychotic therapy to range from 5-78% and "clinically significant' elevations in 0-15%; lists).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, only one of which was attributed to chlorpromazine, the only antipsychotic medication listed).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 cases [0.6%] were attributed to antipsychotic agents, including 3 due to quetiapine and 2 to olanzapine]).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.musil.2015.73">Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2015;<span class="ref-vol">14</span>:73–96.</span> [<a href="/pubmed/25400109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25400109</span></a>]<div><i>(Extensive systematic review of the literature on the problem of weight gain during therapy with antipsychotic agents mentions that weight gain of 7% or more occurs in 18-40% of patients on olanzapine and averages +2.0 to + 4.3 kg, rates being higher than any other atypical antipsychotics, the majority of weight gain occurring during the first 6-12 months but not leveling off thereafter even with long term use).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF51">Drugs for psychotic disorders. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2016;<span class="ref-vol">58</span>(1510):160–4.</span> [<a href="/pubmed/27960194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27960194</span></a>]<div><i>(Concise review of medications available in the US for therapy of psychotic disorders; mentions that olanzapine and ziprasidone can cause DRESS syndrome, but does not mention ALT elevations or hepatotoxicity for any of the agents discussed).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.morl_ncoarasa.2016.3947">Morl&#x000e1;n-Coarasa MJ, Arias-Loste MT, Ortiz-Garc&#x000ed;a de la Foz V, Mart&#x000ed;nez-Garc&#x000ed;a O, Alonso-Mart&#x000ed;n C, Crespo J, Romero-G&#x000f3;mez M, et al.  Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <span><span class="ref-journal">Psychopharmacology (Berl). </span>2016;<span class="ref-vol">233</span>:3947–52.</span> [<a href="/pubmed/27620899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27620899</span></a>]<div><i>(Among 205 patients started on atypical antipsychotic agents between 2005 and 2012 followed using surrogate markers for fatty liver disease and for fibrosis [Fib-4], 48 [25%] patients developed evidence of fatty liver disease as assessed by a fatty liver index score, driven largely by weight gain [91%] and increases in waist circumference [69%] and triglycerides [54%]).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.d_nmez.2017.293">D&#x000f6;nmez YE, &#x000d6;zcan &#x000d6;, Soylu N, Sar&#x00131;o&#x0011f;lu FK, Selimo&#x0011f;lu A. Management of hepatotoxicity Induced by the use of olanzapine. <span><span class="ref-journal">J Child Adolesc Psychopharmacol. </span>2017;<span class="ref-vol">27</span>:293–4.</span> [<a href="/pubmed/28398814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28398814</span></a>]<div><i>(15 year old male with new onset schizophrenia was started on olanzapine and developed abnormal ALT levels [84 U/L] within 2-8 weeks, which resolved with starting ursodiol and vitamin E allowing for continuation of olanzapine).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.baeza.2018.463">Baeza I, de la Serna E, Calvo-Escalona R, Merch&#x000e1;n-Naranjo J, Rodr&#x000ed;guez-Latorre P, Mart&#x000ed;nez-Cantarero MC, Andr&#x000e9;s P, et al.  One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: is there a link with metabolic syndrome? <span><span class="ref-journal">J Child Adolesc Psychopharmacol. </span>2018;<span class="ref-vol">28</span>:463–73.</span> [<a href="/pubmed/29975563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29975563</span></a>]<div><i>(Among 216 children and adolescents starting atypical antipsychotics, mean weight gain at 6 months was 6.5 kg and mean ALT levels increased by 8.6 U/L, while among 37 taking olanzapine mean weight gain was 10.3 kg and ALT increase 2.6 U/L; increases in ALT associated most closely with development of the metabolic syndrome, mean ALT increasing by 27.8 U/L at 6 months).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.g_mezlumbreras.2018.e601">G&#x000f3;mez-Lumbreras A, Marcos-Fosch C, Aguilera C. Psychotropic drugs and liver toxicity. <span><span class="ref-journal">Am J Ther. </span>2018;<span class="ref-vol">25</span>:e601–e602.</span> [<a href="/pubmed/30188878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30188878</span></a>]<div><i>(Woman developed jaundice 4 months after starting paroxetine [40 mg daily] and olanzapine [2.5 mg daily] [bilirubin 7.3 mg/dL, ALT 984 U/L, Alk P 174 U/L], resolving within 3 weeks of stopping both).</i></div></div></li><li><div class="bk_ref" id="Olanzapine.REF.dusi.2019.175">Dusi N, Comacchio C, Lasalvia A. Late-onset cholestatic liver injury during combination treatment with chlorpromazine and olanzapine: a case report. <span><span class="ref-journal">J Clin Psychopharmacol. </span>2019;<span class="ref-vol">39</span>:175–6.</span> [<a href="/pubmed/30640795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30640795</span></a>]<div><i>(40 year old man develop jaundice 10 days after increasing the dose of olanzapine [from 10 to 15 mg daily] which he had taken for 8 years and while also receiving chlorpromazine for 15 months [bilirubin 26.6 rising to 33.3 mg/dL, ALT 51 U/L, Alk P 285 U/L], biopsy showing cholestatic hepatitis and jaundice persisting for 3 months).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548842</span><span class="label">PMID: <a href="/pubmed/31644149" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644149</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Ofloxacin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Olaparib/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548842&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548842/?report=reader">PubReader</a></li><li><a href="/books/NBK548842/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548842" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548842" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Olanzapine. [Updated 2020 Jul 1].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548842/pdf/Bookshelf_NBK548842.pdf">PDF version of this page</a> (143K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Olanzapine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Olanzapine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Olanzapine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Olanzapine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4867738" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4867738" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4867738" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643626" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lurasidone</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lurasidone<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643910" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cariprazine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cariprazine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643928" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Quetiapine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Quetiapine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643422" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Asenapine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Asenapine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21348048" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report</a><span class="source">[ 2010]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">McDonagh M, Peterson K, Carson S, Fu R, Thakurta S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">2010 Jul</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644149" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644149" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468cc60831bd466686d58a">Olanzapine - LiverTox</a><div class="ralinkpop offscreen_noflow">Olanzapine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:44:55-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal105&amp;ncbi_phid=CE8C884204689E110000000000A80039&amp;ncbi_session=CE8C88420468CC61_0168SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548842%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548842&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548842/&amp;ncbi_pagename=Olanzapine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C88420468CC61_0168SID /projects/books/PBooks@9.2 portal105 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>